CMS Issues Decision Memo Broadening Coverage of Next Generation Sequencing Testing for Advanced Breast and Ovarian Cancer

CMS issues its decision memo that revises and expands on the coverage for next generation sequencing (NGS) as a diagnostic laboratory test for ovarian and breast cancer when selected criteria are met.

This expansion of coverage builds on the original NCD that had provided coverage for NGS testing for certain relapsed and advanced stage cancers.

As proposed, CMS gives the local contractors discretion as to whether to cover NGS testing for other indications.

Decision Memo for NGS for Medicare Beneficiaries with Advanced Cancer